– Bispecific Antibody for Cancer Treatment Optimized by GlymaxXR Technology
ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus’ grant of an exclusive license to Hangzhou, Zhejiang Province based Betta Pharmaceuticals Co., Ltd to develop and commercialize in China Merus’ novel MCLA-129, BiclonicsR bispecific antibody for the potential treatment of cancer, which utilizes ProBioGen’s GlymaxXR antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancing technology for greater cell-killing potential.
Merus’ use of the GlymaxXR ADCC enhancement technology in MCLA-129 is the result of an agreement executed between ProBioGen and Merus in 2016. Under the terms of that agreement, Merus obtained non-exclusive rights to use the GlymaxXR technology for Merus’ BioclonicsR pipeline of bispecific antibodies designed to treat various forms of cancer to enhance their ADCC activity. MCLA-129 is the third commercial GlymaxXR license activated by Merus after MCLA128 anti-Her2/Her3 and MCLA-158 anti-EGFRxLGR5 bispecific antibodies.
GlymaxXR is a stable modification, applicable to any producer cell, leading it to produce antibodies without fucose in the sugar chain. Such GlymaxXR-modified, afucosylated antibodies recruit and activate immune effector cells much more effectively, possess a much higher tumor cell killing activity and potentially require lower doses.
ProBioGen offers access to GlymaxXR royalty-free as part of cell line development service projects or as standalone technology licenses.
About Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity is an important antibody function, leading to the selectively killing of target cells, i.e. cancerous cells or pathogen-infected cells. Several therapeutic antibody drugs on the market rely on ADCC as mechanism of action. ADCC enhancement has the potential to increase the therapeutic effect and/or to greatly reduce antibody dosage requirements, resulting in fewer side-effects and treatment costs.
About GlymaxXR –www.GlymaxX.de
The GlymaxXR technology, developed by ProBioGen, prevents the synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked antibody carbohydrate part. The absence of fucose is known to greatly enhance ADCC. The GlymaxXR technology is based on the stable introduction of a gene for an enzyme which literally eliminates the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxXR can be applied to both novel and already existing antibody producer cell lines and entire antibody expression and discovery platforms, without negatively affecting their productivity or product characteristics. Moreover, it is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species. GlymaxXR can be rapidly applied in a few weeks to any existing antibody producer cell line, can be used in the context of ProBioGen’s pre-engineered GlymaxXR host cells, or can be introduced into entire animal cell expression platforms by modifying the host cell line.
ProBioGen offers its GlymaxXR technology royalty-free as service or as individual license.
About ProBioGen –www.probiogen.de
ProBioGen is a specialist for the development and manufacturing of complex therapeutic glyco-proteins. Combining both state-of-the-art development platforms together with intelligent product-specific technologies yields biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen is operational since more than 20 years and is located in Berlin, Germany.
Contact ProBioGen AG:Dr Gabriele SchneiderChief Business Officer ProBioGen AG Goethestr. 54 13086 Berlin, Germany Phone: +49(0)30-924-006-0 Email:[email protected]
(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)